February 8, 2024.
The Atmo Gas Capsule has been safely ingested more than 1,000 times during formal, ethics-approved clinical studies.
February 8, 2024.
The Atmo Gas Capsule has been safely ingested more than 1,000 times during formal, ethics-approved clinical studies.
December 14, 2023.
Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.
More than 200 patients were recruited in a multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.
November 16, 2023.
An editorial published in the journal Alimentary Pharmacology and Therapeutics describes Atmo Biosciences’ gas-sensing capsule as disruptive technology that has enabled unlocking of key aspects of microbial metabolism, especially with respect to carbohydrate fermentation.
November 13, 2023.
Atmo Biosciences is pleased to announce that the Japan Patent Office has granted a patent related to key intellectual property for Atmo’s ingestible gas-sensing capsule.
October 26, 2023.
Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI).
October 19, 2023.
The Atmo Gas Capsule could be used to help understand and monitor duodeno-gastric reflux and provide insight into its connection to delayed gastric emptying, according to an investigation by researchers from Monash University and Western Sydney University.
October 3, 2023.
Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
September 25, 2023.
Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can help diagnose functional gastrointestinal disorders (FGIDs), which affect almost 40 per cent of Australians1.
August 25, 2023.
Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.
August 10, 2023.
Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).